Apcotex Industries – Investor Presentation Summary
Key Operational Highlights
- Sales volume grew 7% year-on-year in Q2 FY27
- Export volumes recovered in Q2-FY27, reversing the decline witnessed in Q1-FY27
- Manufacturing capacity: Taloja Facility - 1,03,000 MTPA Synthetic Latex and 7,000 MTPA High Styrene Rubber; Valia Facility - 21,000 MTPA Nitrile Rubber and Allied Products plus 50,000 MTPA Nitrile Latex Plant
- Workforce strength of over 550 fulltime employees
Key drivers of operational performance: Higher volumes and improved margins drove operational performance. Export volume recovery contributed to growth.
Segment-wise Performance
Not Specified
Financial Highlights
Q2 FY27 Performance:
- Revenue: ₹4,989 Mn (48.2% YoY growth)
- EBITDA: ₹583 Mn (43.6% YoY growth)
- PAT: ₹348 Mn (37.5% YoY growth)
- EPS: ₹6.72/share (37.7% YoY growth)
- EBITDA Margin: 11.69% (37 bps decline YoY)
- PAT Margin: 6.98% (53 bps decline YoY)
H1 FY27 Performance:
- Revenue: ₹10,246 Mn (43.8% YoY growth)
- EBITDA: ₹1,754 Mn (121.2% YoY growth)
- PAT: ₹1,138 Mn (155.7% YoY growth)
- EPS: ₹21.95/share (156.1% YoY growth)
- EBITDA Margin: 17.12% (599 bps improvement YoY)
- PAT Margin: 11.11% (486 bps improvement YoY)
YoY/QoQ comparison: Q2 revenue declined 5.1% QoQ from Q1's ₹5,256 Mn, while PAT declined 55.9% QoQ from Q1's ₹789 Mn
Drivers of financial performance: Higher volumes and improved margins driven by operational efficiencies
Key Risks: Working capital requirements continued at elevated level due to higher input costs
Geographical Revenue Split
Not Specified
Balance Sheet Snapshot
As of H1-FY27:
- Shareholders Fund: ₹7,132 Mn
- Equity Share Capital: ₹104 Mn
- Total Non-Current Liabilities: ₹815 Mn
- Total Current Liabilities: ₹3,680 Mn
- Total Non-Current Assets: ₹5,487 Mn
- Total Current Assets: ₹6,140 Mn
- Cash & Cash Equivalents: ₹148 Mn
- Other Bank Balances: ₹245 Mn
- Inventories: ₹1,722 Mn
- Trade Receivables: ₹3,214 Mn
Financial Health Insights: Company remains Net Cash Positive as of September 30, 2026
Capex & Cash Flow Health
Capital Expenditure: ₹2,100 Mn capex project approved by the Board for expansion at Valia plant, execution remains largely on track
Investment Rationale: Focus on capacity expansion at Valia plant
Strategic & R&D Initiatives
Investments in Innovation: Strong Research & Development base enabling development, manufacture and export of products to compete effectively against global players
Strategic Rationale: Expanding production capacity through Valia plant expansion
Industry Trends & Business Environment
Not Specified
Management Commentary & Growth Outlook
Strategic Outlook: Delivered the strongest-ever half-yearly financial performance in the company's history, with record EBITDA, PBT and PAT
FY Guidance: Not Specified
Risks and Opportunities: Working capital requirements continued at elevated level due to higher input costs